The combination of prostate health index and multiparametric magnetic resonance imaging in prostate cancer diagnosis: efficacy analysis in different PSA ranges and its clinical decision-guiding value - Takeaways - MDSpire

The combination of prostate health index and multiparametric magnetic resonance imaging in prostate cancer diagnosis: efficacy analysis in different PSA ranges and its clinical decision-guiding value

  • By

  • Jin-feng Pan

  • Yin-zhi Chen

  • Su-ying Wang

  • Zhen-ya Zhao

  • Da-wei Ren

  • Rui Su

  • Xiao-long Jia

  • Jun-hui Jiang

  • Qi Ma

  • October 22, 2025

  • 0 min

Share

  • 1

    Prostate cancer (PCa) is a leading cause of cancer death in men, emphasizing the need for timely and accurate diagnosis.

  • 2

    The combination of Prostate Health Index (PHI) and multiparametric MRI (mpMRI) improves PCa detection rates compared to PSA alone.

  • 3

    PHI is FDA-approved for diagnosing PCa in men with PSA levels between 2.0-10.0 ng/ml, highlighting its clinical utility.

  • 4

    The study included 120 patients, revealing a 40% PCa detection rate, with 30.8% classified as clinically significant.

  • 5

    Combining PHI with mpMRI reduces the need for repeat biopsies, enhancing patient management and minimizing complications.

Original Source(s)

The combination of prostate health index and multiparametric magnetic resonance imaging in prostate cancer diagnosis: efficacy analysis in different PSA ranges and its clinical decision-guiding value

  • by Jin-feng Pan, Yin-zhi Chen, Su-ying Wang, Zhen-ya Zhao, Da-wei Ren, Rui Su, Xiao-long Jia, Jun-hui Jiang, Qi Ma

  • October 22, 2025

Related Content

MRI as a screening tool for prostate cancer: current evidence and future challenges

Grading urothelial carcinoma with probe-based confocal laser endomicroscopy during flexible cystoscopy

Combined T2 and diffusion-weighted MR imaging with template prostate biopsies in men suspected with prostate cancer but negative transrectal ultrasound-guided biopsies